Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT-MG study of eculizumab biomarkers in generalized myasthenia gravis
jRCTs031190015Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Complement protein concentration in plasma, MG-related antibody titer in serum and 1 more. Started Aug 2019; status: completed.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs031190015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190015.